Skip to main content
. 2020 Jul 23;10:12348. doi: 10.1038/s41598-020-69366-4

Figure 1.

Figure 1

Patient flowchart. *Among the two MSH-H patients, only one received pembrolizumab treatment and showed disease progression. These patients were only included in ‘toxicity analysis’, and not in ‘efficacy analysis.’